“…Furthermore, the antigen is of relatively low cost to manufacture, has minimal regulatory and market acceptance issues and development of an accurate and relatively inexpensive antibody test to the antigen is possible [10]. In this study, we evaluate the levels of naturally acquired antibodies to TT in wild and domestic ducks from Australia, the immunogenicity of TT in Muscovy ducks, and interference by TT on H6-or TT-seroconversion in ducks given separate TT and H6N2 AI vaccines or combined TT/H6N2 vaccines.…”